About AMW Pharmaceuticals
AMW Pharmaceuticals is a company based in Warngau (Germany) founded in 2008 by Wilfried Fischer was acquired by Yunfeng Capital in July 2018. It operates as a Professional Services and Reseller / Distribution. AMW Pharmaceuticals has raised $6.36 million across 4 funding rounds from investors including European Investment Bank, Hybio Pharmaceutical and KfW. The company has 78 employees as of December 31, 2021. AMW Pharmaceuticals offers products and services including Goserelin Implant, Leuprorelin Implant, and Drug Delivery Systems. AMW Pharmaceuticals operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Warngau, Germany
- Employees 78 as on 31 Dec, 2021
- Founders Wilfried Fischer
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Amw Gmbh
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$6.36 M (USD)
in 4 rounds
-
Latest Funding Round
$30.08 M (USD), Debt – Conventional
Jan 04, 2018
-
Investors
European Investment Bank
& 8 more
-
Employee Count
78
as on Dec 31, 2021
-
Acquired by
Yunfeng Capital
(Jul 05, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of AMW Pharmaceuticals
AMW Pharmaceuticals offers a comprehensive portfolio of products and services, including Goserelin Implant, Leuprorelin Implant, and Drug Delivery Systems.
Implant used for treating hormone-sensitive tumors globally.
Implant designed for hormone-sensitive tumor treatment worldwide.
Biodegradable systems developed for controlled drug release.
People of AMW Pharmaceuticals
Unlock access to complete
Funding Insights of AMW Pharmaceuticals
AMW Pharmaceuticals has successfully raised a total of $6.36M across 4 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $30.08 million completed in January 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in AMW Pharmaceuticals
AMW Pharmaceuticals has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include European Investment Bank, Hybio Pharmaceutical and KfW.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Finance and advisory services for infrastructure projects are provided.
|
Locked | Locked | Locked | |
|
High-tech industries are targeted for investments by Bayern Kapital.
|
Locked | Locked | Locked | |
|
Healthcare-focused private equity investments are managed by SHS Capital.
|
Locked | Locked | Locked |
Investor details for AMW Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AMW Pharmaceuticals
Investment portfolio details for AMW Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - AMW Pharmaceuticals
Detailed financials for AMW Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Amw Pharmaceuticals Comparisons
Peer comparison for AMW Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AMW Pharmaceuticals
AMW Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of AMW Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Amw Pharmaceuticals
Complete news archive for AMW Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AMW Pharmaceuticals
AMW Pharmaceuticals was founded in 2008 and raised its 1st funding round 6 years after it was founded.
AMW Pharmaceuticals is headquartered in Warngau, Germany. It is registered at Warngau, Bavaria, Germany.
Friedrich Tegel is the current CEO of AMW Pharmaceuticals.
AMW Pharmaceuticals is a funded company, having raised a total of $6.36M across 4 funding rounds to date.
As of Dec 31, 2021, the latest employee count at AMW Pharmaceuticals is 78.
AMW Pharmaceuticals, based in Germany, is focused on providing innovative drug delivery systems using biodegradable technologies. The company is involved in the pharmaceutical sector, offering solutions like Goserelin and Leuprorelin implants for hormone-sensitive tumor treatments. Their services include contract development and manufacturing, supporting global pharma and biotech partners. Advanced production facilities are utilized to cover the entire pharmaceutical value chain, ensuring cost-efficient therapies and improved patient adherence.
AMW Pharmaceuticals's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
AMW Pharmaceuticals offers Goserelin Implant, Leuprorelin Implant, and Drug Delivery Systems.
AMW Pharmaceuticals has 9 investors. Key investors include European Investment Bank, Hybio Pharmaceutical, KfW, Bayern Kapital, and SHS Capital.